SCHEMBL819787

SCHEMBL819787

O=S(=O)(O)c1ccc(CBr)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
TSHR P16473 3/20 0.50
ALDH1A1 P00352 3/20 0.50
NT5E P21589 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
TDP1 Q9NUW8 1/20 0.45
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
POLB P06746 1/20 0.42
CYP2D6 P10635 1/20 0.42
CA2 P00918 6/20 0.40
CA1 P00915 4/20 0.40
CA12 O43570 3/20 0.40
CA4 P22748 3/20 0.40
CA6 P23280 3/20 0.40
CA5A P35218 3/20 0.40
CA7 P43166 3/20 0.40
CA9 Q16790 3/20 0.40
CA14 Q9ULX7 3/20 0.40
CA5B Q9Y2D0 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL26654445 0.98 LMNA (0.50) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL2881344 0.98 LMNA (0.50) LMNATSHRALDH1A1NT5ESMN1; SMN2
Hydrochloric Acid SCHEMBL23781867 0.98 LMNA (0.50) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL30968190 0.82 LMNA (0.48) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL314445 0.82 LMNA (0.48) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL17044644 0.80 LMNA (0.46) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL9619529 0.80 LMNA (0.56) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL1148233 0.80 HTR6 (0.47) LMNATSHRALDH1A1CES2CES1
SCHEMBL11583429 0.80 LMNA (0.56) LMNATSHRALDH1A1NT5ESMN1; SMN2
SCHEMBL150334 0.79 LMNA (0.77) LMNATSHRALDH1A1NT5ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408047-B1 PROCESS FOR PREPARATION OF ERYTHROMYCIN COMPOUNDS UBE INDUSTRIES (JP) 2005-10-26 EP claimed
US-6906039-B2 Process for preparation of erythromycin compounds UBE INDUSTRIES, LTD. (JP) 2005-06-14 US claimed
US-20040192902-A1 Process for preparing erythromycin compound UBE INDUSTRIES, LTD. (JP) 2004-09-30 US claimed
EP-1408047-A1 PROCESS FOR PREPARATION OF ERYTHROMYCIN COMPOUNDS Ube Industries, Ltd. (JP) 2004-04-14 EP claimed
EP-0338004-B1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE Deutsche Carbone AG (DE) 1993-04-07 EP claimed
US-5164424-A POLYMER HAVING A BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR PRODUCING SAME AND USE THEREOF DEUTSCHE CARBONE AG (DE) 1992-11-17 US claimed
EP-0338004-A1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE. GFT GES FUER TRENNTECHNIK (DE) 1989-10-25 EP claimed
WO-1988004677-A1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE GFT GESELLSCHAFT FÜR TRENNTECHNIK MBH (DE) 1988-06-30 WO claimed
CN-119060221-A Sulfonic acid functionalized polymer, ion exchange membrane and application thereof 佛山绿动氢能科技有限公司 2024-12-03 CN disclosed
CN-118420813-A Sulfonated vinyl polymer, composite material, and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-08-02 CN disclosed
US-20230118459-A1 ANTIVIRAL TREATMENT ECOSYNTH NV (BE) 2023-04-20 US disclosed
EP-4114376-A1 ANTIVIRAL TREATMENT Ecosynth (BE) 2023-01-11 EP disclosed
US-10727516-B2 Compound and polymer electrolyte membrane using same LG CHEM, LTD. (KR) 2020-07-28 US disclosed
EP-3235809-B1 COMPOUND AND POLYMER ELECTROLYTE MEMBRANE USING SAME LG CHEMICAL LTD (KR) 2019-10-02 EP disclosed
EP-0338004-B1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE Deutsche Carbone AG (DE) 1993-04-07 EP disclosed
US-5164424-A POLYMER HAVING A BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR PRODUCING SAME AND USE THEREOF DEUTSCHE CARBONE AG (DE) 1992-11-17 US disclosed
EP-0338004-A1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE. GFT GES FUER TRENNTECHNIK (DE) 1989-10-25 EP disclosed
EP-0161482-B1 FLUORINATED ANILINE DERIVATIVES AND THEIR USE Roche Diagnostics GmbH (DE) 1989-09-13 EP disclosed
WO-1988004677-A1 POLYMER WITH BETAINE STRUCTURE, SOLUTION DIFFUSION MEMBRANE, PROCESS FOR THEIR MANUFACTURE AND USE GFT GESELLSCHAFT FÜR TRENNTECHNIK MBH (DE) 1988-06-30 WO disclosed
EP-0161482-A1 Fluorinated aniline derivatives and their use Roche Diagnostics GmbH (DE) 1985-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230118459-A1 ANTIVIRAL TREATMENT MAVS, ACE, ACE2 LMNA 1578/4885TSHR 4316/4885ALDH1A1 4719/4885
US-20040192902-A1 Process for preparing erythromycin compound RIOX2, RPS6KA6, ERG28 LMNA 2306/4885TSHR 2966/4885ALDH1A1 2882/4885
US-10727516-B2 Compound and polymer electrolyte membrane using same TMEM109, PXMP4, VMA21 LMNA 2972/4885TSHR 4620/4885ALDH1A1 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.